Lynx Capital
VC Fund
Shanghai, China
Lynx Capital is a healthcare and life science-focused fund that invests in innovative companies in Western countries in both therapeutics and medical technology, with the possibility of collaborating with Chinese companies to explore the Chinese market.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Lynx Capital invests in
Stages Lynx Capital invests in
Countries Lynx Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Health Care 4 (80%)
- Medical 2 (40%)
- Biotechnology 2 (40%)
- Medical Device 2 (40%)
- Oncology 1 (20%)
Stage
- Series A 2 (40%)
- Venture - Series Unknown 2 (40%)
- Seed 1 (20%)
Country
- Finland 3 (60%)
- United States 2 (40%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Flora Gao
Executive
|
Executive | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Marginum is a university-based medical technology startup developing fluorescence-based tissue detection systems. The company’s data-driven solutions enable monitoring of tissues during cancer surgery and treatments. The products are derived from state-of-the-art research to improve surgical performance and cost-effectiveness. Marginum’smultidisciplinary team works in close cooperation with academic, clinical and industrial experts to ensure its technological solutions’ seamless clinical compatibility. | $2.9M / Seed / Aug 22, 2025 | ||
| Bindex® is – in addition to DXA devices – the only device that can be used for osteoporosis diagnostics with international guidelines (ISCD) and the Finnish Current Care Guidelines (04/2014).Bindex® is applied by measuring the cortical thickness of tibia. The results, combined with other patient data, are used to estimate the hip region’sbone mineral density. Bone mineral density values (g/cm2) are normally only received via the large DXA devices used in hospitals.Bindex®’s quickness and simplicity make its use possible in high volume risk group screenings. It makes the identification of an osteoporosis risk possible before the first bone fracture has even occurred. Thus, it both improves the patient’s quality of life and saves on public health care expenses. | Series A / Aug 20, 2024 | ||
| Elucida Oncology focuses on transforming outcomes for patients with primary solid tumors and metastatic cancer. The company utilizes the novel target or clear capabilities of its ultra-small C-Dot cancer-targeting particle platform across diagnostic imaging, surgical, and a wide range of therapeutic applications. | $22.9M / Venture - Series Unknown / Jun 15, 2023 | ||
| They exist to develop curative solutions that achieve total and faster healing for non-healing wounds and other complex inflammatory diseases with their four-in-one biologic drug, AUP-16. Their goal is to create solid Phase 2 clinical efficacy data in diabetic foot ulcers and non-clinical proof-of-concept data in other inflammatory diseases by endof 2022, and to engage with strategic partners to ensure that this game changing technology benefits millions of patients. | $10M / Series A / Mar 30, 2023 | ||
| Novuson, a spinout from the University of Washington’s highly regarded Applied Physics Laboratory’s Center for Industrial and Medical Ultrasound, is developing its Direct Therapeutic Ultrasound (DTU) technology platform for coagulation and hemostatic control in surgical and trauma procedures. DTU technology should enable clinicians to performsurgeries more quickly and to rapidly control bleeding associated with traumatic injuries. The company founders are Stuart B. Mitchell, PhD. and Francesco P. Curra, Ph.D.Novuson creates tools that reduce operational cost and operating time, eliminating bleeding complications and enhancing patient outcomes. These automatic devices use direct therapeutic ultrasound energy for fast and robust hemostasis, cauterization and division. The devices cauterize tissue from the inside out, creating a well-defined, controlled plane of cauterization. The company was founded in 2014 and based in Bothell, Washington. | Venture - Series Unknown / Jan 01, 2017 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Lynx Capital invest in?
Lynx Capital invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Venture - Series Unknown stage. Most of the 5 investments tracked by Shizune back companies in Finland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Lynx Capital?
Public channels for Lynx Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Lynx Capital?
The team at Lynx Capital includes Flora Gao (Executive). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
